Antibody Discovery Service via Polyclonal Antibody Sequencing.
Mass spectrometry based in vivo antibody discovery platform. A flexible end-to-end workflow delivering developable, functional mAbs unseen by other modalities alone.
Antibody Discovery Platform.
How It Works.
Our discovery process offers a complete suite of services to take you from immunization and de novo polyclonal antibody (pAb) sequencing, through to recombinant mAb expression, mAb characterization and ultimately lead selection.
Our unique technology gives us the ability to sequence antibody proteins directly from a complex mixture, using only mass spectrometry. We call this REpAb®. Leverage the entire natural immune response and begin the search for your lead molecule directly from functional native circulating antibodies.
Species Agnostic mAb Discovery
We can work with many species, including human antibodies and humanized animal. We are experienced in rabbit, alpaca, sheep, dog, chicken, human, and goat. Working with protein means you can test interaction with homologous targets in other model species early in your discovery campaign.
Immunization
We have experience with tolerance breaking strategies such as using novel immunization, adjuvant and modification techniques to elicit an immune response. Additionally, a unique advantage of the REpAb® platform for tolerance busting is using different host species to raise antibodies against conserved proteins.
The REpAb® Advantage.
What Are You Missing?
Depending on when and where you sample B-Cells for genomic sequencing, you may miss the best antibodies. We find unique antibodies not present in NGS data, which is crucial for therapeutic antibody discovery. If you’re not looking at the circulating antibody proteins, you’re missing out.
Broaden the Search.
Discoveries come easier when you:
- Search a bigger space and
- Improve the search strategy
REpAb® considers the entire immune response (up to 1018 sequences) and leverages biology to select the best antibodies.
Quality vs Quantity of Hits.
We start with the most abundant, functional, circulating antibodies from the host organism because they offer:
- Greater epitope diversity
- A wide range of binding affinities
- Reduced immunogenicity
REpAb® returns a few handfuls of the best leads and dozens of related sequences to fall back on.
Success Stories.
“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”
Getting Started.
Deliverables
- 5-30 mAb sequences with paired HC and LC
- Additional CDR clusters sequences
- Recombinantly expressed mAbs
- SPR binding kinetics, screening and full profile
- HDX-MS 3D epitope mapping report
“Our cutting edge antibody discovery service can select the very best antibodies out of millions of naturally evolved forms. REpAb® starts with a complex mixture of antibodies known to have affinity for your target. From there, we employ proprietary chemistry and various separation techniques, followed by dozens of LC-MS/MS runs and other mass spectrometry experiments. The resulting data is analyzed by our own de novo sequencing and assembly algorithms to produce full length IgG sequences.
Talk to Our Scientists.
We Have Sequenced 8000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 8000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics
Talk to our scientists. We have sequenced over 8000 antibodies and we are eager to help you.
The Science of Antibody Discovery.
Antibody Sequencing & Discovery Services.
Other Antibody Discovery and Characterization Services.
Antibody Sequencing & Discovery Services.
REmAb®
Monoclonal antibody sequencing from small antibody samples, no need for hybridoma or DNA information. Full sequence in record time.
Explore REmAb®
REpAb®
Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore REpAb®
MATCHmAb™
Antibody sequence confirmation service by real-time peptide mapping.
Explore MATCHmAb
HDX-MS
Mass spectrometry based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with high confidence and resolution.
Explore HDX-MS
SPR Analysis
Label-free evaluation of antibody-antigen binding relies on Surface Plasmon Resonance technology. Combined with our expertise in antibody interactions, this results in high sensitivity and low noise even in complex analytes.
Explore SPR Analysis
NovorIg™
Quantify the immune response by accurately profiling the vast antibody-protein repertoire, its different isotypes, and subtypes in serum over time.
Explore Immune Response Profiling